Perspective Therapeutics (CATX) Receivables (2011 - 2026)
Perspective Therapeutics (CATX) reported Receivables of $58000.0 for Q1 2026, down 25.64% on a YoY basis from $78000.0 in Q1 2025, and up 262.5% sequentially from $16000.0 in Q4 2025.
Perspective Therapeutics (CATX) Receivables (2011 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 16 years of Receivables data on file, last reported at $58000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables fell 25.64% year-over-year to $58000.0; the trailing twelve-month figure through Mar 2026 stood at $58000.0 (down 25.64% YoY), and the FY2025 full-year result was $16000.0, down 97.35% from the prior year.
- Receivables grew to $58000.0 in Q1 2026, from $16000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $2.1 million in Q1 2022 to a low of $16000.0 in Q4 2025.
- A 5-year average of $837823.5 and a median of $999000.0 in 2024 frame the typical range for Receivables.
- Peak annual rise in Receivables reached 58.45% in 2025, while the deepest fall reached 97.35% in 2025.
- Tracing CATX's Receivables over 5 years: stood at $1.4 million in 2022, then slipped by 13.92% to $1.2 million in 2023, then sank by 48.68% to $603000.0 in 2024, then tumbled by 97.35% to $16000.0 in 2025, then soared by 262.5% to $58000.0 in 2026.
- Business Quant data shows CATX's Receivables at $58000.0 in Q1 2026, $16000.0 in Q4 2025, and $179000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | 8.21 Bn |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 3.57 Bn |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 6.64 Bn |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 3.03 Bn |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | 973.00 Mn |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 4.50 Bn |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | 1.55 Bn |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 3.80 Bn |
| 10 | Perspective Therapeutics | 296.01 Mn | 296.01 Mn | - | 58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 179,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 999,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.21 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 2.14 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | 2.05 Mn |